Skip to main content
Journal cover image

Hymenolepis diminuta-based helminth therapy in C3(1)-TAg mice does not alter breast tumor onset or progression.

Publication ,  Journal Article
Sauer, S; Beinart, D; Finn, SMB; Kumar, SL; Cheng, Q; Hwang, SE; Parker, W; Devi, GR
Published in: Evol Med Public Health
2021

BACKGROUND AND OBJECTIVES: An individual's risk of breast cancer is profoundly affected by evolutionary mismatch. Mismatches in Western society known to increase the risk of breast cancer include a sedentary lifestyle and reproductive factors. Biota alteration, characterized by a loss of biodiversity from the ecosystem of the human body as a result of Western society, is a mismatch known to increase the risk of a variety of inflammation-related diseases, including colitis-associated colon cancer. However, the effect of biota alteration on breast cancer has not been evaluated. METHODOLOGY: In this study, we utilized the C3(1)-TAg mouse model of breast cancer to evaluate the role of biota alteration in the development of breast cancer. This model has been used to recapitulate the role of exercise and pregnancy in reducing the risk of breast cancer. C3(1)-TAg mice were treated with Hymenolepis diminuta, a benign helminth that has been shown to reverse the effects of biota alteration in animal models. RESULTS: No effect of the helminth H. diminuta was observed. Neither the latency nor tumor growth was affected by the therapy, and no significant effects on tumor transcriptome were observed based on RNAseq analysis. CONCLUSIONS AND IMPLICATIONS: These findings suggest that biota alteration, although known to affect a variety of Western-associated diseases, might not be a significant factor in the high rate of breast cancer observed in Western societies. LAY SUMMARY: An almost complete loss of intestinal worms in high-income countries has led to increases in allergic disorders, autoimmune conditions, and perhaps colon cancer. However, in this study, results using laboratory mice suggest that loss of intestinal worms might not be associated with breast cancer.

Duke Scholars

Published In

Evol Med Public Health

DOI

ISSN

2050-6201

Publication Date

2021

Volume

9

Issue

1

Start / End Page

131 / 138

Location

England

Related Subject Headings

  • 4206 Public health
  • 3104 Evolutionary biology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sauer, S., Beinart, D., Finn, S. M. B., Kumar, S. L., Cheng, Q., Hwang, S. E., … Devi, G. R. (2021). Hymenolepis diminuta-based helminth therapy in C3(1)-TAg mice does not alter breast tumor onset or progression. Evol Med Public Health, 9(1), 131–138. https://doi.org/10.1093/emph/eoab007
Sauer, Scott, Dylan Beinart, Sade M. B. Finn, Sereena L. Kumar, Qing Cheng, Shelley E. Hwang, William Parker, and Gayathri R. Devi. “Hymenolepis diminuta-based helminth therapy in C3(1)-TAg mice does not alter breast tumor onset or progression.Evol Med Public Health 9, no. 1 (2021): 131–38. https://doi.org/10.1093/emph/eoab007.
Sauer S, Beinart D, Finn SMB, Kumar SL, Cheng Q, Hwang SE, et al. Hymenolepis diminuta-based helminth therapy in C3(1)-TAg mice does not alter breast tumor onset or progression. Evol Med Public Health. 2021;9(1):131–8.
Sauer, Scott, et al. “Hymenolepis diminuta-based helminth therapy in C3(1)-TAg mice does not alter breast tumor onset or progression.Evol Med Public Health, vol. 9, no. 1, 2021, pp. 131–38. Pubmed, doi:10.1093/emph/eoab007.
Sauer S, Beinart D, Finn SMB, Kumar SL, Cheng Q, Hwang SE, Parker W, Devi GR. Hymenolepis diminuta-based helminth therapy in C3(1)-TAg mice does not alter breast tumor onset or progression. Evol Med Public Health. 2021;9(1):131–138.
Journal cover image

Published In

Evol Med Public Health

DOI

ISSN

2050-6201

Publication Date

2021

Volume

9

Issue

1

Start / End Page

131 / 138

Location

England

Related Subject Headings

  • 4206 Public health
  • 3104 Evolutionary biology